Allen AM et al. Restricted field IMRT dramatically enhances IMRT planning for mesothelioma. Int J Radiat Oncol Biol Phys 2007;69(5):1587-92. Abstract
Ceresoli GL et al. Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): A multicentre, single-arm phase 2 trial. Lancet Oncol 2019;20(12):1702-9. Abstract
Forde PM et al. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) — A PrECOG LLC study. ASCO 2020;Abstract 9003.
Krug LM et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27(18):3007-13. Abstract
Mun EJ et al. Tumor-treating fields: A fourth modality in cancer treatment. Clin Cancer Res 2018;24(2):266-75. Abstract
Rimner A et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol 2016;34(23):2761-8. Abstract
Rosenzweig KE et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2012;83(4):1278-83. Abstract
Rusch VW et al. Should the esophageal cancer staging system be revised? J Thorac Cardiovasc Surg 2003;125(5):992-3. Abstract
Vogelzang NJ et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-44. Abstract
Weder W et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007;18(7):1196-202. Abstract
Zalcman G et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016;387(10026):1405-14. Abstract